Gourgue et al. reported that blocking the Apelin inhibits TNBC growth during obesity by changing the tumour microenvironment and via the apelinergic system interference, which makes it a potential treatment strategy for patients with BC and obesity [35]. This evidence concerns the gene APLN and obesity due to melanocortin 4 receptor deficiency.